# Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

> **NCT04989816** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 95 (actual)

## Conditions studied

- Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT04989816
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-20
- **Primary completion:** 2023-06-16
- **Final completion:** 2024-02-28
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989816, "Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04989816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*